Clinical trials - Press Releases

Date	Title	Company
23-Nov-2022	World’s first clinical trial to test new drug glenzocimab for heart attacks	University of Birmingham
23-Nov-2022	Clinion Achieves GDPR Compliance, continuing its commitment to data privacy and security	Clinion
19-Nov-2022	AJG publishes data from HighTide Therapeutics' Phase 2 study of HTD1801 Treatment in Adults with PSC	HighTide Therapeutics
18-Nov-2022	MODERNA WINS REUTERS PHARMA AWARDS FOR DELIVERING INCLUSIVE TRIALS	Moderna
17-Nov-2022	Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02	Evaxion
15-Nov-2022	Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON	Sequana Medical
15-Nov-2022	Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an ‘off-the shelf’ Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer	Nouscom
15-Nov-2022	Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia	Rejuvenate Biomed
14-Nov-2022	Mural Health Enters the Market to Disrupt Clinical Trial Participant Management Through the Launch of Mural Link Platform	Mural Health
14-Nov-2022	HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China	HUTCHMED
08-Nov-2022	Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types	Albireo Pharma
08-Nov-2022	Nouscom’s Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors	Nouscom
08-Nov-2022	Australia’s Telix Pharmaceuticals Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study	Telix Pharmaceuticals
08-Nov-2022	Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma	Cartherics
04-Nov-2022	Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers	Transgene
04-Nov-2022	Servier and OSE Immunotherapeutics announce completion of patient enrollment in the Phase 2a clinical trial of OSE-127/S95011 in primary Sjögren’s syndrome	Servier and OSE
03-Nov-2022	medmix Drug Delivery (Haselmeier™) and AARDEX® Group Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials	AARDEX® Group
01-Nov-2022	CD Bioparticles Introduces Hydrophilic Coatings for Medical Applications	CD Bioparticles
01-Nov-2022	Amerigo Scientific Launches New Polyclonal Antibody to Human Blood Coagulation Factor XIII	Amerigo Scientific
28-Oct-2022	dMed \| Clinipace announce corporate name change to Caidya	ramarketing